{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T21:11:15Z","timestamp":1783717875662,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.rpth.2025.102856","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T12:01:00Z","timestamp":1744891260000},"page":"102856","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of direct oral anticoagulants compared with warfarin in antiphospholipid syndrome. Results of a multicenter retrospective cohort study"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8953-4030","authenticated-orcid":false,"given":"Maha A.T.","family":"Elsebaie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Wickham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"DeBragga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Fedewa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Amgad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane Jungyoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Eshaghpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Crowther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0817-9848","authenticated-orcid":false,"given":"Manila","family":"Gaddh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2025.102856_bib1","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.17219\/acem\/65853","article-title":"Direct oral anticoagulants in patients with thrombophilia: challenges in diagnostic evaluation and treatment","volume":"25","author":"Undas","year":"2016","journal-title":"Adv Clin Exp Med"},{"key":"10.1016\/j.rpth.2025.102856_bib2","first-page":"688","article-title":"Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants","volume":"126","author":"Weitz","year":"2016","journal-title":"Pol Arch Med Wewn"},{"key":"10.1016\/j.rpth.2025.102856_bib3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102856_bib4","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1056\/NEJMoa035241","article-title":"A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome","volume":"349","author":"Crowther","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.102856_bib5","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1538-7836.2005.01340.x","article-title":"A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)","volume":"3","author":"Finazzi","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102856_bib6","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/art.23109","article-title":"A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies","volume":"57","author":"Ruiz\u2013Irastorza","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rpth.2025.102856_bib7","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1160\/TH04-11-0723","article-title":"Bleeding and re-thrombosis in primary antiphospholipid syndrome on oral anticoagulation: an 8-year longitudinal comparison with mitral valve replacement and inherited thrombophilia","volume":"93","author":"Ames","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102856_bib8","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/jth.14398","article-title":"Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis","volume":"17","author":"Elsebaie","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102856_bib9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials","volume":"81","author":"Khairani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rpth.2025.102856_bib10","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/jth.14453","article-title":"Follow-up to comment on \u201cDirect oral anticoagulants in patients with venous thromboembolism and thrombophilia: systematic review and meta-analysis.\u201d","volume":"17","author":"Elsebaie","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102856_bib11","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.102856_bib12","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/bloodadvances.2021005808","article-title":"Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial","volume":"6","author":"Woller","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2025.102856_bib13","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1177\/0961203315624555","article-title":"Direct oral anticoagulants in antiphospholipid syndrome: a real life case series","volume":"25","author":"Betancur","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.rpth.2025.102856_bib14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11239-016-1420-x","article-title":"Direct oral anticoagulants in hypercoagulable states","volume":"43","author":"Kunk","year":"2017","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.rpth.2025.102856_bib15","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/MBC.0000000000000247","article-title":"Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism","volume":"26","author":"Sciascia","year":"2015","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.rpth.2025.102856_bib16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.thromres.2016.12.009","article-title":"The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome","volume":"152","author":"Malec","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2025.102856_bib17","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1177\/0961203315581207","article-title":"Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II\/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE","volume":"24","author":"Cohen","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.rpth.2025.102856_bib18","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.rpth.2025.102856_bib19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(11)60178-5","article-title":"Chronic kidney disease","volume":"379","author":"Levey","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2025.102856_bib20","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1182\/blood-2014-08-532820","article-title":"Rare bleeding disorders: diagnosis and treatment","volume":"125","author":"Palla","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.102856_bib21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.rpth.2025.102856_bib22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/mpr.124","article-title":"Graphing survival curve estimates for time-dependent covariates","volume":"11","author":"Schultz","year":"2002","journal-title":"Int J Methods Psychiatr Res"},{"key":"10.1016\/j.rpth.2025.102856_bib23","doi-asserted-by":"crossref","first-page":"985","DOI":"10.2105\/AJPH.86.7.985","article-title":"Are smokers with alcohol disorders less likely to quit?","volume":"86","author":"Breslau","year":"1996","journal-title":"Am J Public Health"},{"key":"10.1016\/j.rpth.2025.102856_bib24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/sim.4780030106","article-title":"A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias","volume":"3","author":"Simon","year":"1984","journal-title":"Stat Med"},{"key":"10.1016\/j.rpth.2025.102856_bib25","series-title":"Applied survival analysis: regression modeling of time-to-event data","author":"Hosmer","year":"2008"},{"key":"10.1016\/j.rpth.2025.102856_bib26","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.rpth.2025.102856_bib27","first-page":"1","article-title":"Antiphospholipid syndrome and challenges with direct oral anticoagulants","volume":"81","author":"Booth","year":"2020","journal-title":"Br J Hosp Med (Lond)"},{"key":"10.1016\/j.rpth.2025.102856_bib28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.4059","article-title":"Trends in the use of oral anticoagulants for adults with venous thromboembolism in the US, 2010-2020","volume":"6","author":"Iyer","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.rpth.2025.102856_bib29","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rpth.2025.102856_bib30","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2025.102856_bib31","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"Ordi\u2013Ros","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rpth.2025.102856_bib32","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40814-020-00594-1","article-title":"A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome","volume":"6","author":"Legault","year":"2020","journal-title":"Pilot Feasibility Stud"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925001803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925001803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T08:37:36Z","timestamp":1755074256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037925001803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2475037925001803"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2025.102856","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of direct oral anticoagulants compared with warfarin in antiphospholipid syndrome. Results of a multicenter retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2025.102856","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102856"}}